Take a deep breath: Asthma drug study failed to include Black and Puerto Rican children who could benefit most

Two pharmaceutical companies — Sanofi and Regeneron Pharmaceuticals — just published the results of a study of their blockbuster Dupixent medicine for treating children between ages 6 and 11 with moderate to serious uncontrolled asthma.